. Patients requiring treatment for CLL had increased risk of infection with the highest risks on patients treated with purine analoges or alemtuzumab. Patients treated with ibrutinib had higher risk of infection compared to treatment naive patients.
Patient with CLL are reported to have a propensity to infection with encapsulated bacteria. A Danish study reported on 317 positive blood cultures in 3,822 patients, which occurred at a rate of 15.5 per 1,000 patient-years in treatment naive and 62.3 per 1,000 patient-years in treated patients. The most commonly isolated